DOCSLIB.ORG

Sr. No. Company Name Page No. Sr. No. Company Name Page No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sr. No. Company Name Page No. Sr. No. Company Name Page No Index Sr. No. Company Name Page no. Sr. No. Company Name Page no. 1 3M in India 01 46 Merck Ltd 173 2 Abbott India Ltd 03 47 Meridian Enterprises Pvt. Ltd 174 3 Ajanta Pharma Ltd 17 48 Meyer Organics Pvt. Ltd 175 4 Alkem Laboratories Ltd 18 49 MGRM Medicare Ltd 178 5 Allergan Healthcare India Pvt. Ltd 19 50 Microwin Labs Private Ltd 180 6 Aristo Pharmaceuticals Pvt. Ltd 20 51 MITS Nutraceuticals Pvt. Ltd 181 7 Azzura Pharmaconutrition Pvt. Ltd 25 52 MSD 182 8 Bausch & Lomb Eyecare (I) Pvt. Ltd 26 53 MSN Laboratories Pvt. Ltd 183 9 Bayer CropScience Ltd 27 54 Mylan Pharmaceuticals Pvt. Ltd 185 10 Bharat Serum & Vaccines Ltd 28 55 Nanz Medi Science Pharma (P) Ltd 186 11 Biocare ‐ Neuvithrah Nutrition Pvt. Ltd 29 56 Naprod Life Sciences Pvt. Ltd 187 12 Biochem Pharmaceutical Industries Ltd 31 57 Neon Laboratories Ltd 188 13 Biocon Ltd 33 58 New Medicon Pharma Lab Pvt. Ltd 194 14 Blue Cross Laboratories Ltd 36 59 Nipro India Corporation Pvt. Ltd 195 15 British Biologicals 37 60 Nobel Biocare 196 16 BSN Medical Pvt. Ltd 39 61 Novartis India Ltd 201 17 Cadila Pharmaceuticals Ltd 40 62 Novo Nordisk India Pvt. Ltd 204 18 CareNow Medical Pvt. Ltd 43 63 Pfizer Ltd 207 19 Celon Laboratories Ltd 44 64 Primecure Medicines Ltd 211 20 Cipla Ltd 45 65 Ranbaxy Laboratories Ltd 212 21 Claris Lifesciences Ltd 82 66 Raptakos, Brett & Co. Ltd 213 22 Coloplast India 84 67 Roche Ltd 215 23 Curatio Healthcare 85 68 Samarth Life Sciences Pvt. Ltd 216 24 Dishman Group 87 69 Sandoz Private Ltd 218 25 Dr. Reddy's Laboratories 88 70 Sanjivani Paranteral Ltd 219 26 Elder Pharamaceuticals Ltd 104 71 Shreya Life Sciences Pvt. Ltd 220 27 Eli Lilly and Company (India) Pvt. Ltd 108 72 Siemens 223 28 Emcure Pharmaceuticals Ltd 109 73 Sun Pharmaceutical Industries Ltd 224 29 Feron Life Sciences Pvt. Ltd 113 74 Themis Medicare Ltd 244 30 Fourrts (India) Laboratories Pvt. Ltd 114 75 Torrent Pharmaceuticals Ltd 246 31 Fusion Healthcare Pvt. Ltd 117 76 Troikaa Pharmaceuticals Ltd 262 32 Gentech Healthcare 118 77 TTK Healthcare 264 33 GlaxoSmithKline Consumer Healthcare Ltd 119 78 UCB India Private Ltd 265 34 Glenmark Pharmaceuticals Ltd 121 79 Unichem Laboratories Ltd 267 35 Hexagon Nutrition Pvt. Ltd 136 80 Unimark Remedies Ltd 276 36 Indian Immunologicals Ltd 137 81 USV Ltd 277 37 Intas Pharmaceuticals Ltd 138 82 Venkateshwara Hatcheries Private Ltd 285 38 Ipca Laboratories Ltd 144 83 Venus Remedies Ltd 286 39 Johnson & Johnson Ltd 150 84 Virchow Laboratories Ltd 287 40 KLM Laboratories Pvt. Ltd 151 85 Win‐Medicare Private Ltd 288 41 La Renon Healthcare Pvt. Ltd 152 86 Wockhardt Ltd 290 42 Lupin Pharmaceuticals 154 87 Wyeth Limited 292 43 Lyka Labs Ltd 156 88 Zuventus Healthcare Ltd 293 44 Macleods Pharmaceuticals Ltd 157 89 Zydus Cadila Healthcare Ltd 297 45 Mead Johnson & Company 172 Sr. No. Product Name Ingredient PKG. 1 1015 Steridrape Surgical 1X10S 2 1243 B Comply Steam Chem Integrator Surgical 100 Drsg 3 1527‐0 Transpore Surgical 1 4 1527‐1 Transpore Surgical 12 Roll 5 1527‐2 Transpore Surgical 6 Roll 6 1527‐3 Transpore Surgical 4 7 1530‐0 Micropore 1/2"X10Yds Surgical Box 8 1530‐1 Micropore Surgical 10 9 1530‐1 Micropore 1"X10Yds Surgical Box 10 1530‐2 Micropore 2"X10Yds Surgical Box 11 1530‐3 Micropore 3"X10Yds Surgical Box 12 1530‐S‐1Micropore1"X5.46Yd Micropore Tape Surgical Box 13 1535‐1 In Micropore Surgical 1X12 14 1535‐2 In Micropore Surgical 6 15 1535‐3 In Micropore Surgical 4 16 1537‐Nexcare Opticlude Orthopaedic Patch Surgical Box 17 1539 Nexcare 3.25"X2.25"/Bx Opticlude Surgical 18 1546 Steristrips Surgical 1 19 1547 Steristrip Surgical 50 Drsg 20 1610 Tegaderm 4Bx/Cs Surgical 100 Drsg 21 1610‐S‐20 Tegaderm Surgical 20 22 1623 W Tegaderm 100 Drsg Surgical 100 Drsg 23 1623‐S‐20 Tegaderm Small Pack(6Cmx7Cm) Surgical Box 24 1624 W Tegaderm Film 100 Dsrw Surgical 100 Drsg 25 1624W‐S‐20 Tegaderm Surgical 20 26 1626W(8526) Tegaderm 50 Drsg Surgical 50 Drsg 27 1626W‐S‐10 Tegaderm Surgical Box 28 1627 Tegaderm Film 20 Drsg Surgical 20 29 1633 Tegaderm Iv 100 Surgical Box 30 1635 W Tegaderm 50 Iv Dressimg Surgical 50 Drsg 31 1635‐S‐10 Tegaderm Surgical 10 32 3345 Cavilon No String Barr Film Surgical 3 ml 33 3345 Cavilon Sting Barrier Film Spr Surgical 3 ml 34 3346 Cavilon No Sting Barrier Film Surgical 28ml 35 3582‐(8582) Transparent Dressing (50) Surgical Box 36 3582(8582)‐S‐10 Tegaderm + Pad Surgical 10 37 3584 Tegaderm With Pad 60Mx100 Surgical Box 38 3587 Tegaderm With Pad (9Cmx10) Surgical 1 39 3591 Transparent Dressing 9Omx2 Surgical Box 40 3593 Tegaderm Trans Drsg Surgical 1 1 Sr. No. Product Name Ingredient PKG. 41 3671A Soft Cloth Dressing With Pad Surgical 1 42 3M Elastic Adhesive Ban Surgical 43 3M Monitoring Electrode Electrode Monitoring 44 3M Skin Preparation 10%Pi Solution Povidone Iodine Ip 10% 500 ml 45 3M Skin Preparation 5% Pi Solution Povidone Iodine 5% 500 ml 46 3M Skin Preparation 5%Pi Solution Povidone Iodine 5% 100 ml 47 3M Skin Preparation10% Pi Soln Povidone Iodine Ip 10% 100 ml 48 9670 Surgical Clipper Surgical 1 49 9680 Clipper Blade Surgical 1 50 9680 Surgical Clipper Surgical 1 51 A8804 Disp Surgical Gown Surgical Xl 52 A8804Disp Surgical Gown Surgical 1 X 30 53 Avagard Chlorhexidine Gluconate 1% + Ehtyl Alcohol 61%W/V 500 ml 54 Coban 1581‐1Inx5Yds Surgical Box 55 Cold/Hot Pack1X2 Surgical 2 56 Cold/Hot Singles Pack Surgical 1 57 Crepe Bandage 10 Cm (4 Meter) Surgical 3 58 Crepe Bandage.10Cmx4Meter Surgical Box 59 Durapro 1"1538 Surgical 1 60 Eab 10 Cmx4/6Mts Surgical 3 mtr 61 Elastic Adhesive Bandage Surgical 3 62 Ioban 6640 Surgical 10 63 Ioban 6650 Surgical 10 64 Medipore 3Inch (2863‐3)S/C Tape Surgical 1 65 Medipore 4Inch X 10Yd (2864) Surgical 66 Micropore Tape 1 X "5 Surgical Tape 1 S 67 Micropore Tape 2 X "5 Surgical Tape 1 S 68 Micropore Tape 3 X "5 Surgical Tape 1 S 69 Rapid 1 Ltr Multi Enzyme Cleaner 1 Ltr 70 Scotchmagic Tape With Dispenser Surgical 1 71 Silicon Tape‐1" (2770S‐1) Surgical 1" 72 Tegaderm Small Pack (16 Surgical 73 Transpore Tape 1527‐1" Surgical 1 74 Transpore Tape Size:1/2 Surgical 2 Sr. No. Product Name Ingredient PKG. Antioxidant Complex With Vitamins A,C ,E,Zinc & 1 A07 Caps 10 Selenium 2 Acitrom 0.5 Tab Nicoumalone 0.5Mg 10 3 Acitrom 1Mg Tab (30) Nicoumalone 1Mg 30 4 Acitrom 2Mg Tab Nicoumalone 2Mg 30 5 Acitrom 3 Mg Tab Nicoumalone 3Mg 30 6 Acitrom 4 Mg Tab (30) Nicoumalone 4Mg 30 7 Acuvert Tab Prochloperazine Melate 5Mg 9 Tab 8 Acuvin Tab Tramadol Hcl 37.5Mg + Paracetamol 325Mg 10 9 Adequet 100 Tab Quetiapine Fumarate 100Mg 10 10 Adequet 50 Mg Tab Quetiapine Fumarate 50Mg 10 11 Adiza Tab Ilaprazole 10Mg 10 Mg 12 Advacort‐1 Tab Deflazacort 1Mg 6 Tab 13 Advacort‐18 Tab Deflazacort 18Mg 6 Tab 14 Advacort‐6 Tab Deflazacort 6Mg 6 Tab 15 Aggribloc 5 Iv Tirofiban 5Mg 100 ml 16 Agoviz Tab Agomelatine 25Mg 10 17 Ambisome 50 Injn. Amphotericin 50Mg 1 18 Ambistryn ‐S Inj 0.75Gm Streptomycin 0.75Gm Vial 19 Ambistryn ‐S Inj 1Gm Streptomycin Sulphate 1Gm Vial 20 Anetol Paracetamol 1000Mg 100 ml 21 Apnicaf 1.5Ml Oral Solution Caffeine Citrate 20Mg 1.5 ml 22 Apnicaf 3Ml Inj Caffeine Citrate 20Mg 3 ml 23 Apnicaf 3Ml Oral Solution Caffeine Citrate 20Mg 3 ml 24 Aquaviron Injn Thiomersal 0.01%W/V + Testosterone 25Mg/Ml 1 ml 25 Arachitol Chewable Tab Calcium 4 Tab 26 Arachitol Inj 3L Vitamin D3 3L Iu 6X 1ml 27 Arachitol Inj 6L Vitamin D3 6L Iu 6X 1ml 28 Arachitol Tab Vitamin D3 60000 Iu 4 29 Arachitol‐O Tablets Vitamin D3 60000 Iu 30 S 30 Avomine Promethazine 25Mg 10 Tab 31 Bactrim Ds Tab Sulphomethaxazole 800Mg + Trimethoprim 160Mg 10 32 Basiton Forte Tab Multivitamin With Biotin 15 33 Becozym C Forte Tabs Multivitamin 15 34 Becozyme Syr Multivitamin 100 ml 35 Benadon 40 Tabs Pyridoxine Hydrochloride 40Mg 10 36 Betonin Ast Syrup Multivitamin 170 ml 37 Betonin Osted Multivitamins ,Stimulating 10 38 Betonin Xt Softlet Multivitamin 15 39 Bezalip Retard Tabs Benzafibrate 800Mg 10 40 Bezalip Tabs Benzafibrate 400Mg 10 3 Sr. No. Product Name Ingredient PKG. 41 Biosugarnil 10Mg Tab Serratopeptidase 10Mg 10 42 Biosugarnil 20Mg Tab Serratopeptidase 20Mg 10 Tab 43 Biosugarnil 5Mg Serratopeptidase 5Mg 10 Paracetamol 500Mg + Diclofenac K 50Mg + 44 Biozobid Plus Tab 10 Serratiopeptidase 10Mg 45 Biozobid Tab Diclofenac Sodium 50Mg + Serratiopeptidase 10Mg 10 Tab 46 Bivasave Surgical 1S 47 Bizobid Tab Diclofenac Sodium 50Mg + Serratiopeptidase 10Mg 10 48 Brufen 200 Mg Tab Ibuprofen 200Mg 15 49 Brufen 400 Mg Tab Ibuprofen 400Mg 15 50 Brufen Junior Syp Ibuprofen 100Mg/5Ml 60 ml 51 Brufen Mr Cap Ibuprofen 400Mg + Tizanidine 2Mg 10 52 Brugel Actifast Flurbiprofen 5% W/W 30 gm 53 Bruspaz 4 Mg Tab Thiocolchicoside 4Mg + Diclofenac 50Mg 10 54 Bruspaz 8Mg Tab Thiocolchicoside 8Mg + Diclofenac 50Mg 10 55 Caat 10Mg Atorvastatin 10Mg 15 Tab 56 Caat 20 Tab. Atorvastatin 20Mg 15 57 Caat 40 Tab Atorvastatin 40Mg 10 58 Caat 80 Tab Atorvastatin 80Mg 10 59 Caat F Tab Atorvastatin 10Mg + Fenofibrate 145Mg 10 60 Calaptin 40 Tabs Verapamil Hcl 40Mg 10 61 Calaptin 80 Tabs Verapamil Hcl 80Mg 10 62 Calaptin Sr 120 Tabs Verapamil Hcl 120Mg 10 63 Calaptin Sr 240 Tabs Verapamil Hcl 240Mg 10 64 Cardules 10 Caps Nifedepine 10Mg 10 65 Cardules 10 Retard Nifedepine 10Mg 10 66 Cardules 20 Retard Nifedepine 20Mg 10 67 Cardules Plus 10 Caps Nifedepine 10Mg + Atenelol 50Mg 10 68 Carvetrend 25 Tabs Carvedilol 25Mg 10 69 Carvetrend 6.25 Tabs Carvedilol 6.25Mg 10 70 Celex Od Clarithromycin 500Mg 500 mg 71 Celex Od 500Mg Clarithromycin 5 Tab 72 Clinaxon 500 Tab Citicoline 500Mg 10 73 Clinaxon Inj Citicoline 250Mg/Ml 74 Clinaxon Od Tab Citicoline 1000Mg 10 75 Clinaxon P Tab Citicoline 500Mg + Piracetam 800Mg 10 76 Clozam 10Mg Clobazam 10Mg 10 77 Clozam 5Mg Clobazam 5Mg 10 78 Colospa 135Mg Tab Mebeverine Hcl 135Mg 10 79 Colospa Retard Cap Mebevaerine Hcl 200Mg 10 80 Contramal 100 Inj Tramadol Hcl 100Mg/2Ml 2ml 4 Sr.
Load more

Recommended publications
  • First Quarter 2019
    Press release First quarter 2019 Issued: Wednesday, 1 May 2019, London U.K. GSK delivers sales of £7.7 billion +6% AER, +5% CER Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER Financial highlights • Pharmaceuticals sales £4.2 billion, +4% AER, +2% CER; Vaccines £1.5 billion, +23% AER, +20% CER; Consumer Healthcare £2.0 billion, flat AER, +1% CER. • Total Group operating margin 18.6%. Adjusted Group operating margin 28.2%, +1.6 percentage points AER, +1.0 percentage point CER (Pharmaceuticals 29.8%; Vaccines 40.3%; Consumer Healthcare 21.7%). Benefits from strong sales growth and phasing of R&D. • Total EPS 16.8p, +50% AER, +42% CER. • Adjusted EPS 30.1p, +22% AER, +18% CER, driven by strong operating performance, continued financial efficiencies, reduction in minority share and a one-off benefit to associates. • Net cash flow from operations £663 million. Free cash flow £165 million. • 19p dividend declared for the quarter; continue to expect 80p for full year 2019. • 2019 Guidance reaffirmed. Product and pipeline highlights • Total HIV sales £1.1 billion, +7% AER, +4% CER, including Juluca sales of £70 million. - Dovato (dolutegravir+lamivudine), first once-daily 2-drug regimen for treatment-naive HIV patients, launched in US. - Long-acting cabotegravir+rilpivirine filed in the US for treatment of HIV. • Total new Respiratory product sales £631 million, +29% AER, +25% CER, including Trelegy £87 million; Nucala £152 million. • Shingrix sales £357 million driven by continued strong launch execution in US. • Continued
    [Show full text]
  • Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG
    EN Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 11/01/2001 Also available in the CELEX database Document No 301M2192 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 11.01.2001 SG(2000)D/285020 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information ARTICLE 6(1)(b) DECISION omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case No COMP/M.2192 – SmithKline Beecham/Block Drug Notification of 17.11.2000 pursuant to Article 4 of Council Regulation No 4064/89 1. On 17 November, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (“the Merger Regulation”), by which the UK company, SmithKline Beecham plc (“SB”) notified its intention to acquire sole control over the US company, Block Drug Company Inc. (“Block Drug”), through purchase of shares. 2. Following examination of the notification, the Commission has concluded that the notified operation falls within the scope of the said Council Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA agreement.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]
  • Annual Report 2017
    Annual Report Image HIV virus 2 017 GSK Annual Report 2017 GSK is a science-led global healthcare company In the Strategic report Our new CEO discusses Measuring performance 2017 performance and our and managing risk new long-term priorities See pages 05–07 See pages 18–21 How we create Innovation and Performance long-term value in each of our three businesses See pages 08–09 See pages 22–41 Industry trends How our three businesses together contribute to our Trust priority See pages 10–11 See pages 42–51 Our new long-term priorities: Financial review Innovation, Performance and Trust See pages 12–17 See pages 52–78 Cover image Cautionary statement 30 years after developing the first HIV See the inside back cover of this document medicine, our research into treatment and for the cautionary statement regarding prevention of HIV continues. We remain forward-looking statements. at the forefront of helping people living with HIV, driving innovation and working with communities all over the world. 01 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Our financial performance in 2017a £30.2bn AER +8% £6.7bn AER +51% Group turnover CER +3% New product salesb CER +44% £4.1bn AER +57% £8.6bn AER +12% Total operating profit CER +39% Adjusted operating profit CER +5% 31.4p AER +67% 111.8p AER +11% Total earnings per share CER +36% Adjusted earnings per share CER +4% £6.9bn £3.4bn £3.9bn 80p Net cash flow from Free cash flow Dividends declared 2017 dividend operating activities for 2017 per
    [Show full text]
  • GSK to Acquire Full Ownership of Consumer Healthcare Business
    Accelerating our strategy: GSK to acquire full ownership of Consumer Healthcare Business Buyout of Novartis’ stake Strategic review of Horlicks and other Consumer Healthcare Nutrition products Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.
    [Show full text]
  • راتفرannual Report 2019
    THE BLUE DOT GlaxoSmithKline Consumer Healthcare Pakistan Limited 35 - Dockyard Road, West Wharf, Karachi - 74000 GlaxoSmithKline Consumer Healthcare Pakistan Limited REPORT 2019 رفتارis a member of GlaxoSmithKline group of companies. ANNUAL © GlaxoSmithKline Consumer Healthcare Pakistan Limited GLAXOSMITHKLINE CONSUMER HEALTHCARE PAKISTAN LIMITED GSK Consumer Healthcare Pakistan Limited is proud to present its Annual Report for the year 2019. This report focuses on Stakeholder Information, Corporate Governance, Directors’ Report and Financial Statements for the year ended December 31, 2019. For any feedback, suggestions or queries kindly contact the following: Talal Javed Ahmed Chief Financial Ocer E-mail: [email protected] Abdul Haseeb Pirzada Head of Corporate Aairs and Administration Email: [email protected] رفتار STRONGER, FEARLESS, AGILE Amongst many our ‘Raftaar – speed’ stands out alone - GSK Consumer Healthcare Pakistan Limited's (GSK CH's) identity is accounted for being undoubtedly the best fast-moving consumer healthcare company in Pakistan. We set foot in this journey back in 2017 when GSK CH took its Flight (Uraan) with relentless motivation and unwavering energy. We moved forward in 2018 and created our Identity (Pehchaan) when we had committed to deliver only the best to our consumers. Keeping our core values at heart, we remained patient focused, transparent, respectful and most importantly carried our integrity above all. These elements led us to this day where we excelled in this corporate race with a new profound strength; accelerating with a speed (Raftaar) not just to be the best but to be the number one choice for our consumers in Pakistan. This strength for speed was not easy in such economic times with currency devaluation, regulatory frameworks and a competitive landscape.
    [Show full text]
  • Investor Information Information Investor Information
    Strategic report report Governance and and remuneration remuneration Financial statements statements Investor information information Investor information In this section Quarterly trend 244 Pharmaceuticals turnover 246 Vaccines turnover 248 Five year record 249 Product development pipeline 255 Products, competition and intellectual property 258 Principal risks and uncertainties 261 Share capital and control 276 Dividends 278 Financial calendar 2021 279 Annual General Meeting 2021 279 Tax information for shareholders 280 Shareholder services and contacts 282 US law and regulation 284 Group companies 287 Glossary of terms 299 GSK Annual Report 2020 243 Financial record Quarterly trend An unaudited analysis of the Group results is provided by quarter in Sterling for the financial year 2020. Income statement – Total 12 months 2020 Q4 2020 Q3 2020 Q2 2020 Q1 2020 Reported Pro-forma Reported Reported Reported Reported £m £% CER% CER% £m £% CER% £m £% CER% £m £% CER% £m £% CER% Turnover Pharmaceuticals 17,056 (3) (1) (1) 4,366 (4) (3) 4,192 (7) (3) 4,102 (5) (5) 4,396 6 6 Vaccines 6,982 (2) (1) (1) 2,012 15 16 2,032 (12) (9) 1,133 (29) (29) 1,805 19 19 Consumer Healthcare 10,033 12 14 (2) 2,360 (8) (7) 2,422 (4) 2 2,389 25 25 2,862 44 46 34,071 1 3 (2) 8,738 (1) – 8,646 (8) (3) 7,624 (2) (3) 9,063 18 19 Corporate and other unallocated turnover 28 1 – – 27 Total turnover 34,099 1 3 (2) 8,739 (2) (1) 8,646 (8) (3) 7,624 (2) (3) 9,090 19 19 Cost of sales (11,704) (1) – (3,171) (2) (2) (2,885) (11) (8) (2,449) (7) (7) (3,199) 17 18 Selling, general
    [Show full text]
  • Annual Report 2016
    Annual Report 2016 2016 saw good sales momentum across Pharmaceuticals, Vaccines and Consumer Healthcare and further pipeline progress We are a global science-led healthcare company. Our three world-leading businesses research and deliver innovative medicines, vaccines and consumer healthcare products. Front cover case study At GSK, innovation underpins each of our three businesses We are using next generation technology return on R&D investment and accelerate to develop new approaches to disease the development of new products that can management and control. In addition to improve patients’ lives. our own research and development, We have an active pipeline of innovative we gain insights through our network of products across six core areas: respiratory, collaborations with biotechs, other HIV and infectious diseases, vaccines, companies and academic institutions. immuno-inflammation, oncology and This enables more efficient trial design rare diseases. and greater use of software, analytics and new technology, all of which is helping to increase our productivity, maximise our Arthur works at our Upper Providence R&D lab Cautionary statement regarding forward-looking statements The Group’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document and written information released, or oral statements made, to the public in the future by or on behalf of the Group, may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.
    [Show full text]
  • Alphabetical Listing by Name Dod UNIFORM OUTPATIENT
    DoD UNIFORM OUTPATIENTFORMULARY Alphabetical Listing by Name This document is current as of July 14, 2021 The availability of formulary items is subject to change. Basic Core Formulary: MTF must have on formulary Uniform Formulary: MTF may have on formulary Nonformulary: MTF must not have on formulary Extended Core Formulary: MTF must be on formulary if includes any drugs from that drug class 1 ABACAVIR Abacavir Capsule, Oral: DoD Uniform Formulary Outpatient Dosage Forms Mapap Extra Strength: 500 mg UNIFORM FORMULARY Elixir, Oral: Solution, Oral: Mapap Children's: 160 mg/5 mL (118 mL, 480 mL) [ethanol free; contains Ziagen: 20 mg/mL (240 mL) [contains methylparaben, propylene glycol, benzoic acid, propylene glycol, sodium benzoate; cherry flavor] propylparaben, saccharin sodium; strawberry-banana flavor] Injection, Solution [preservative free]: Tablet, Oral: Ofirmev: 10 mg/mL (100 mL) Generic: 300 mg Liquid, Oral: Generic: 160 mg/5 mL (120 mL, 473 mL); 500 mg/5 mL (240 mL) Abacavir and Lamivudine Solution, Oral: DoD Uniform Formulary Outpatient Dosage Forms Generic: 160 mg/5 mL (5 mL, 10 mL, 20 mL) UNIFORM FORMULARY Suppository, Rectal: Tablet, Oral: Generic: 120 mg (12s); 325 mg (12s) Generic: Abacavir 600 mg and lamivudine 300 mg Suspension, Oral: Generic: 160 mg/5 mL (5 mL, 10.15 mL, 20.3 mL) Abacavir, Dolutegravir, and Lamivudine Syrup, Oral: DoD Uniform Formulary Outpatient Dosage Forms Triaminic Children's Fever Reducer Pain Reliever: 160 mg/5 mL (118 mL) UNIFORM FORMULARY Tablet, Oral: Tablet, Oral: Generic: 325 mg, 500 mg Triumeq:
    [Show full text]
  • Your 2020 Over-The-Counter Ordering Catalog
    Your 2020 Over-the-Counter Ordering Catalog Hundreds of common health products you can buy with your Gateway Health benefit. Look Inside for More Details and How to Order. Use this Catalog Jan. 1, 2020-Dec. 31, 2020 Y0097_1537_M VISIT US ONLINE AT WWW.FIELDTEX-GATEWAY.COMY0097_1537_M1 2020_Gateway_OTC_Catalog.indd 1 9/26/19 10:01 AM Welcome! Start using your Over-the-Counter (OTC) benefit. Your Gateway Health coverage just keeps getting better. Starting January 1, 2020 you have access to hundreds of retail wellness products when you use your quarterly over-the-counter allowance. And even better, any unused portion of your quarterly allowance can be rolled over to the next quarter. It’s a service powered by our partners at Fieldtex, and it’s unbelievably simple to use. How Much You Get: $300 per Quarter $120 per Quarter Medicare Assured Medicare Assured DiamondSM Members RubySM Members Use this catalog to choose and order your health products from January 1, 2020 to December 31, 2020. All orders must be placed by then. See next page for easy instructions on how to order. 2 CALL US TOLL-FREE AT 1-855-350-0074 (TTY 711) Y0097_1537_M 2020_Gateway_OTC_Catalog.indd 2 9/26/19 10:01 AM Gateway Health Ordering Process 3 Easy Ways to Order Order Online Order by Phone www.Fieldtex-Gateway.com 1-855-350-0074 (TTY 711) Monday-Friday 8:00 AM to 5:00 PM Order by Mail Saturday 9:00 AM to 5:00 PM Fill out the attached mail order form and send it in the postage- Sunday paid envelope.
    [Show full text]
  • Press Release First Quarter 2018
    Press release First quarter 2018 Issued: Wednesday, 25 April 2018, London U.K. GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER Total EPS 11.2p, -48% AER, -33% CER; Adjusted EPS 24.6p, -2% AER, +11% CER Significant currency impact in the quarter reflecting movements in Sterling F inancial highlights • CER sales growth across all 3 businesses. Pharmaceuticals sales £4.0 billion -4% AER, +2% CER; Vaccines £1.2 billion +7% AER, +13% CER; Consumer Healthcare £2.0 billion -3% AER, +2% CER • Adjusted Group operating margin of 26.6%, down 0.2 percentage points AER, up 1.3 percentage points CER. Pharmaceuticals 33.2%; Vaccines 27.4%; Consumer Healthcare 19.4% • Total EPS 11.2p, -48% AER, -33% CER, reflecting revaluation of Consumer Healthcare business following agreement to acquire full ownership • Adjusted EPS 24.6p, -2% AER, +11% CER driven by continued operating and financial efficiencies • Q1 free cash flow £324 million -50% primarily reflecting impact of £317 million Vaccine sales milestone payment to Novartis • 19p dividend declared for quarter. Continue to expect 80p for FY 2018 • Guidance for CER growth in Adjusted EPS for 2018 maintained Novartis transaction • Agreement reached with Novartis to acquire full ownership of Consumer Healthcare business for $13 billion, subject to shareholder approval P roduct and pipeline highlights • Sales of Ellipta Respiratory products, £386 million +25% AER, +34% CER and Nucala £104 million +76% AER, +86% CER. Landmark IMPACT data for Trelegy Ellipta published in NEJM. sNDA approved in US and data submitted to European Medicines Agency to support expanded label.
    [Show full text]